Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer

Med Oncol. 2011 Dec:28 Suppl 1:S246-9. doi: 10.1007/s12032-010-9708-8. Epub 2010 Oct 9.

Abstract

Sorafenib, a new antiangiogenic and antiproliferative agent, is currently used for hepatocellular and renal cell carcinoma. We report here the case of a patient with two cancers, a locally advanced cancer of the piriform sinus and a hepatocellular carcinoma, who was given sorafenib. Tumor response of both cancers might suggest that sorafenib could be effective against head and neck cancer.

Publication types

  • Case Reports

MeSH terms

  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / drug therapy*
  • Head and Neck Neoplasms / complications
  • Head and Neck Neoplasms / diagnosis
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Neoplasm Metastasis / diagnosis
  • Neoplasm Metastasis / drug therapy
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Portal Vein / pathology*
  • Pyridines / therapeutic use*
  • Sorafenib
  • Treatment Outcome
  • Venous Thrombosis / complications
  • Venous Thrombosis / diagnosis
  • Venous Thrombosis / drug therapy*

Substances

  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib